Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

New Hampshire's Medicaid Program Almost Out Of Money
"Rising unemployment and spiking Medicaid and welfare caseloads have put [New Hampshire"s] most recent budget to the test just two weeks after its adoption," New Hampshire Public Radio reports. The state"s Medicaid caseload is just 39 enrollees away from putting the "state"s Medicaid budget in the red."
generic viagra online
Taiwan Rolls Out Plans To Boost Fertility Rates
Targeting the issue of low birth rates, the Taiwanese government implemented the Mega Warmth Social Welfare Program (MWSWP) in 2006 after its fertility rates dipped lower than most industrial nations.
News of the day
FDA Approves TYVASO (Treprostinil) Inhalation Solution For The Treatment Of Pulmonary Arterial Hypertension
United Therapeutics Corporation (Nasdaq: UTHR) announced that the United States Food and Drug Administration (FDA) has approved TYVASO (treprostinil) Inhalation Solution for the treatment of pulmonary arterial hypertension (PAH) using the TYVASO Inhalation System (which includes the Optineb-ir device and accessories). TYVASO is indicated to increase walk distance in patients with NYHA Class III symptoms associated with WHO Group I PAH, which includes multiple etiologies such as idiopathic and familial PAH as well as PAH associated with scleroderma and congenital heart disease.
Diagnostics

2009/044 NICE Issues Final Guidance On The Use Of Rituximab For First Line Chronic Lymphocytic Leukaemia

The National Institute for Health and Clinical Excellence (NICE) has today (22 July) published guidance on the use of rituximab for the first line treatment of chronic lymphocytic leukaemia. The guidance recommends that rituximab should be considered asa possible first treatment for people with chronic lymphocytic leukaemia who are able to take fludarabine in combination with cyclophosphamide. Rituximab should only be used in combination with fludarabine and cyclophosphamide. Rituximab is not recommended in combination with any other chemotherapy agents as a first treatment for chronic lymphocytic leukaemia. Chronic lymphocytic leukaemia is the most common form of adult leukaemia and is a cancer of the white blood cells (lymphocytes). The cancerous lymphocytes multiply in an uncontrolled way and stop normal white blood cells, red blood cells and platelets (blood fragments that have a role in the clotting of blood) from working properly. Dr Carole Longson, NICE Health Technology Evaluation Centre Director said: "After looking at all of the available evidence the independent Appraisal Committee concluded that rituximab, when used as a first line treatment for people with with chronic lymphocytic leukaemia who are able to take fludarabine in combination with cyclophosphamide, represented an effective use of NHS res. This important guidance increases the treatment options available to people with this condition, wherever they live in England and Wales." NICE


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009